ArticleDiscover oncology2025
Characterization, expression, and mutational analysis of endosomal protein lethal giant disc (Lgd/CC2D1A) as a biomarker in patients with T-cell acute lymphoblastic leukemia.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe endosomal pathway plays a crucial role in eukaryotes, and its conservation across evolution underscores its importance in fundamental processes, such as endocytosis, cytokinesis, and autophagy. Dysregulation of the Notch signaling system, essential for growth and development, contributes to cancers like leukemia. In Drosophila melanogaster (DM), specific endosomal genes function as tumor suppressors, regulating Notch signaling, either through promoting Notch degradation or directing its recycling. Nevertheless, it is still unanswered how endosomal genes specifically, lethal giant discs (lgd/CC2D1A), affect Notch-1-mediated transduction in human malignancies, such as T-cell acute lymphoblastic (T-ALL).
aimThis study aimed to comprehensively characterize the (lgd/CC2D1A) CC2D1A/lgd in human T-ALL by performing mutational analysis and sequencing and evaluating its gene and protein expression levels. These analyses were conducted to elucidate better the role of (lgd/CC2D1A)CC2D1A in the pathophysiology of T-ALL and to explore its potential association with the Notch-1 signaling pathway. MATERIALS AND
methodsIn this study, we sequenced the lgd and investigated its expression in peripheral blood samples of human T-ALL samples. We used molecular approaches to analyse the Lgd/CC2D1A gene for mutations and characterize its gene and protein expression across genomic and proteomic datasets.
resultsSequencing data revealed the presence of the lgd variant (CC2D1A) in T-ALL patients and healthy individuals. Lgd and Notch-1 expression were significantly upregulated in T-ALL patients, demonstrating a strong positive correlation at both the genomic and proteomic levels.
conclusionsThrough this analysis, we reported the presence of Lgd with an altered nucleotide sequence in T-ALL patients. We also found its elevated expression compared with healthy controls, which might affect disease progression. Our investigation results also lay the foundation for the possible development of Lgd as a predictive indication for the early identification of T-ALL.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.